Other Science

Domain Therapeutics to Participate at Premier Investor and Healthcare Conferences

Retrieved on: 
Monday, April 8, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, G protein-coupled receptor, Multimedia, Gq alpha subunit, Pharmaceutical industry

Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024:

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announced its President and Chief Executive Officer, Anthony Johnson, M.D., and its Chief Business Officer, Sean A. MacDonald, will participate in the following investor, partnering and healthcare industry conferences in April-May, 2024:
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240408769768/en/
    Anthony Johnson & Sean A. MacDonald (Photo: Domain Therapeutics)
    Location: Metro Toronto Convention Centre (North Building), Toronto, Canada

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Retrieved on: 
Monday, April 8, 2024
Mental Health, Research, Neurology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, SIRS, Schizophrenia, Medication, Clozapine, XETRA, Incidence, Patient, CNS, Peripheral nervous system, Safety, TRS, Schizophrenia International Research Society, Pharmaceutical industry

The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.

Key Points: 
  • The data presented were detailing previously reported scientific results of study 014/015, the future clinical development outlook for evenamide and information on study 008A.
  • As previously announced by Newron, the study showed that the addition of evenamide to antipsychotics was well tolerated, with low incidence of treatment-emergent adverse events.
  • Treatment with evenamide was associated with sustained, clinically significant benefit that increased throughout the one-year course of treatment.
  • Study 008A is a four-week, randomized, double-blind and placebo-controlled study assessing the efficacy, tolerability, and safety of evenamide (30 mg bid).

Innovation Meets Regulation: International Webinar Explored Effective Anti-Smoking Strategies

Retrieved on: 
Tuesday, April 9, 2024
Retail, Other Communications, Public Policy, Technology, Marketing, Consulting, Advertising, Communications, Professional Services, Government, Tobacco, Science, Other Science, Internet, Research, Failure, Tax, Herbal cigarette, Innovation, European Parliament, Risk, Public, Smoker, Policy, Smoke, MEP, Death, Smoking, European, Multimedia, Carcinogen

We Are Innovation hosted the webinar “ Innovation Meets Regulation: The 2024 Effective Anti-Smoking Policies Global Index .” This powerful talk embarked on the official start of the campaign dedicated to the launch of the anti-smoking index .

Key Points: 
  • We Are Innovation hosted the webinar “ Innovation Meets Regulation: The 2024 Effective Anti-Smoking Policies Global Index .” This powerful talk embarked on the official start of the campaign dedicated to the launch of the anti-smoking index .
  • The webinar, featuring Members of the European Parliament, regulatory experts, economists, and innovation experts, shed light on the regulatory frameworks regarding anti-smoking policies from the most prominent global authorities in the field.
  • View the full release here: https://www.businesswire.com/news/home/20240408705665/en/
    Federico N. Fernández stated, “At We Are Innovation, we work on issues that require innovative approaches and solutions.
  • By embracing a forward-thinking approach, we can effectively address the problem of smoking,” summed up Tetiana Rak.

Mountain Valley MD Announces Stock Option Grant

Retrieved on: 
Monday, April 8, 2024
Research, Environment, Fitness & Nutrition, Biotechnology, Pharmaceutical, Health, Agriculture, Natural Resources, Science, Other Science, Consultant, Option, Culture, FRA

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), today announced the grant of stock options pursuant to its existing stock option plan (the “Stock Option Plan”).

Key Points: 
  • Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMDF) (FRA: 20MP), today announced the grant of stock options pursuant to its existing stock option plan (the “Stock Option Plan”).
  • The Board has granted to certain directors, officers, employees and consultants an aggregate of 3,000,000 stock options (the “Options”).
  • The Options vest 20% on the date of grant, 30% on the 6-month anniversary of the date of grant and 50% on the one-year anniversary of the date of grant.
  • The Options have a term of 5 years and are exercisable at $0.06 per share.

AACR 2024: PDC*line Pharma Presents Interim Clinical Results From Last Cohort of Patients in Phase I/II Trial with PDC*lung01 Cancer Vaccine

Retrieved on: 
Monday, April 8, 2024
Stem Cells, Biotechnology, Health, Pharmaceutical, Biometrics, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, KU Leuven, Mutation, Database, Survival, Best, DCR, Patient, Data, Aes, Șaeș, Progression-free survival, AACR, Kaplan–Meier estimator, Clinical trial, Cancer, Injection, ESMO, Safety, Symantec Endpoint Protection, DSMB, Poster, PFS, Vaccine, PDC

PDC*lung01 is the company’s off-the shelf therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC).

Key Points: 
  • PDC*lung01 is the company’s off-the shelf therapeutic cancer vaccine candidate for Non-Small Cell Lung Cancer (NSCLC).
  • The phase I/II trial (PDC-LUNG-101) aimed to assess the safety, tolerability, immunogenicity and preliminary clinical activity of PDC*lung01 in NSCLC patients, alone or in combination with anti-PD-1 treatment.
  • PDC*Line is reporting preliminary efficacy results for 19 evaluable patients in the B2 cohort that reached the 9-month PFS mark.
  • The final analysis of the clinical trial including the 45 patients from the B2 cohort will be conducted in Q3, 2024.

Battelle Delivers Up-Armored Ford Expeditions to U.S. Department of State

Retrieved on: 
Monday, April 8, 2024
Research, Other Defense, Contracts, Technology, Defense, Security, Science, Government Technology, Automotive Manufacturing, Other Technology, Manufacturing, Other Science, Department of Defence, Certification, Organization, Government, Denial-of-service attack, Security Service, DSS, Exploration, United, Ford Motor Company, Ford, Toyota, Ford Expedition, Expedition, Operation, Diplomatics, Feedback

Battelle has delivered four upgraded Ford Expeditions to the United States Department of State (DoS) for testing, evaluation, and certification.

Key Points: 
  • Battelle has delivered four upgraded Ford Expeditions to the United States Department of State (DoS) for testing, evaluation, and certification.
  • Battelle upgraded the Expeditions with armor and technology to meet specific protection mission requirements while leaving the original showroom appearance.
  • Battelle is also producing 229 up-armored Toyota Land Cruiser 200s for DoS that will be delivered within the next 15 months.
  • “We are really proud of these vehicles,” said Battelle Ground Systems Senior Program Manager Jim LaBine.

Applied Physics Launches Warp Drive Simulator

Retrieved on: 
Tuesday, April 9, 2024
Aerospace, Technology, Manufacturing, Security, Other Science, Other Technology, Satellite, Research, Software, Internet, Science, APL, Physics, Classical, Applied physics, Warp, Professional corporation, Journal, Quantum gravity, Multimedia, Weaving

Today, Applied Physics®, a multidisciplinary group of international scientists and engineers, announced the groundbreaking launch of Warp Factory— a toolkit designed for the theoretical testing and advancement of realistic warp drive technologies.

Key Points: 
  • Today, Applied Physics®, a multidisciplinary group of international scientists and engineers, announced the groundbreaking launch of Warp Factory— a toolkit designed for the theoretical testing and advancement of realistic warp drive technologies.
  • View the full release here: https://www.businesswire.com/news/home/20240408213718/en/
    Physicists can generate and refine an array of warp drive designs with Warp Factory by Applied Physics.
  • Science fiction is now inching closer to science fact.”
    The field of warp drives has experienced a resurgence since 2021 when a series of papers, including Applied Physics’ “ Introducing Physical Warp Drives ,” suggested that warp drives could be constructed in accordance with the laws of physics.
  • Operating within the fabric of Applied Physics, the Advanced Propulsion Laboratory (APL) represents the cutting edge of warp drive research.

IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud

Retrieved on: 
Monday, April 8, 2024
Data Management, Biotechnology, Technology, Professional Services, Health, Health Technology, Other Science, Research, Data Analytics, Software, Science, Cloud, CRM, Organization, Partnership, OCE, SVP, Sale, AI, Patient safety, HCP, IQV, Fine chemical

IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry.

Key Points: 
  • IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life sciences industry.
  • Building on the IQVIA Orchestrated Customer Engagement ( OCE ) platform, launched in 2017, the partnership will apply innovations from IQVIA OCE with Salesforce’s Life Sciences Cloud to provide customers with a new single, end-to-end engagement platform.
  • As part of the expanded partnership, IQVIA will license the OCE CRM related software to Salesforce, and the parties will collaborate to accelerate development of Life Sciences Cloud for customer engagement, expected to be available in 2025*.
  • “Our collaboration with IQVIA marks a pivotal moment for Salesforce Life Sciences Cloud innovation.

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Men, Health, Consumer, Other Health, Pharmaceutical, Surgery, Other Science, Research, Medical Devices, Science, Women, Seniors, Clinical Trials, Week, Sciatica, LDH, Incidence, Ferring Pharmaceuticals, Patient, Spinal disc herniation, Șaeș, University, ESI, Quality of life, Manager, University of Illinois Urbana-Champaign, Society, Back pain, LSM, Pain, SAE

"Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."

Key Points: 
  • "Based on these findings, SI-6603 could provide another option where a single injection to the lumbar disc could offer patients significant relief from the unrelenting pain often associated with lumbar disc herniation."
  • An analysis assessing current treatment patterns and gaps in clinical management of patients with newly diagnosed LDH was also presented.
  • The analysis reviewed medical claims data of more than a million U.S. patients over a four-year period.
  • Among patients who received more than one ESI, one in five (22.4%) underwent surgery with 14.2% of those patients receiving repeated surgeries.

Study of NFL Alumni Cohort Finds Majority Suffer From Heart Disease Without Knowing It

Retrieved on: 
Sunday, April 7, 2024
Health, Sports, Football, Other Health, Other Science, Research, Science, Blood pressure, TTE, FACC, African Americans, Prevalence, Aortic stenosis, National Football League, Patient, Education, Ageing, Journal, History, MD, City, Male, American College, TAVR, EKG, AFL, Interventional cardiology, Alumni association, NFL, National Football League Alumni, Hypertension, Pharmaceutical industry

Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) announced the release of data from the HUDDLE study that examined the prevalence of heart disease and associated risk factors among members of the National Football League (NFL) Alumni Association and their families.
  • Results of the HUDDLE study indicated that the prevalence of hypertension in the 498 screened participants was 83.8%, though only about half (46.5%) self-reported a history of hypertension.
  • Conducted across eight U.S. cities in cooperation with NFL Alumni Health, a subsidiary of the NFL Alumni Association, HUDDLE was a cross sectional study of NFL alumni and their family members aged 50 years and above.
  • Study participants self-reported their medical histories and participated in heart health education and screenings that included blood pressure, electrocardiogram (EKG) and echocardiogram.